SCHEMBL4941528

SCHEMBL4941528

Oc1ccc(-c2nnc(O)n2-c2ccccc2Cl)c(O)c1

nearest known ligand 0.61

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 5/20 0.61
PDE2A O00408 2/20 0.41
PDE10A Q9Y233 2/20 0.41
MAOA P21397 1/20 0.39
MAOB P27338 1/20 0.39
ALOX5 P09917 1/20 0.38
ESR1 P03372 2/20 0.37
NOTUM Q6P988 1/20 0.37
BCHE P06276 1/20 0.35
ACHE P22303 1/20 0.35
BACE1 P56817 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL930185 0.86 HSP90AA1 (0.58) HSP90AA1PDE2APDE10AMAOAMAOB
SCHEMBL4936858 0.84 HSP90AA1 (0.60) HSP90AA1MAOBALOX5ESR1
SCHEMBL931818 0.81 HSP90AA1 (0.43) HSP90AA1ALOX5ESR1
SCHEMBL4943310 0.81 HSP90AA1 (0.64) HSP90AA1ALOX5ESR1
SCHEMBL4939622 0.79 HSP90AA1 (0.42) HSP90AA1PDE2APDE10ANOTUM
SCHEMBL930881 0.78 HSP90AA1 (0.50) HSP90AA1PDE2APDE10AMAOBESR1
SCHEMBL4933212 0.76 ESR1 (0.50) HSP90AA1MAOAMAOBESR1NOTUM
SCHEMBL930811 0.76 HSP90AA1 (0.47) HSP90AA1PDE2APDE10AMAOAMAOB
SCHEMBL8930373 0.76 HSP90AA1 (0.73) HSP90AA1
SCHEMBL930835 0.76 HSP90AA1 (0.37) HSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080182857-A1 Triazole Derivatives MERCK PATENT GMBH (DE) 2008-07-31 US claimed
EP-1853570-A2 HSP90-INHIBITING TRIAZOLE DERIVATIVES Merck Patent GmbH (DE) 2007-11-14 EP claimed
WO-2006087077-A2 HSP90-INHIBITING TRIAZOLE DERIVATIVES MERCK PATENT GMBH (DE) 2006-08-24 WO claimed
US-8618285-B2 Triazole derivatives MERCK PATENT GMBH (DE) 2013-12-31 US disclosed
EP-1853570-B1 HSP90-INHIBITING TRIAZOLE DERIVATIVES MERCK PATENT GMBH (DE) 2012-10-24 EP disclosed
US-20080182857-A1 Triazole Derivatives MERCK PATENT GMBH (DE) 2008-07-31 US disclosed
EP-1853570-A2 HSP90-INHIBITING TRIAZOLE DERIVATIVES Merck Patent GmbH (DE) 2007-11-14 EP disclosed
WO-2006087077-A2 HSP90-INHIBITING TRIAZOLE DERIVATIVES MERCK PATENT GMBH (DE) 2006-08-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080182857-A1 Triazole Derivatives HSP90AB1, HSP90AA1, HSP90B1 HSP90AA1 2/4885PDE2A 2759/4885PDE10A 3756/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.